Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.64 |
| ▸ | NPY1R | P25929 | 3/20 | 0.64 |
| ▸ | NPY2R | P49146 | 3/20 | 0.64 |
| ▸ | NPY4R | P50391 | 3/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.60 |
| ▸ | IL1RN | P18510 | 1/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.59 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508663 | 0.99 | NPY1R (0.65) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29577431 | 0.97 | NPY1R (0.66) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29578675 | 0.97 | NPY1R (0.66) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29666338 | 0.96 | GHSR (0.67) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29508679 | 0.94 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29508714 | 0.94 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL30887362 | 0.94 | GHSR (0.67) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29577418 | 0.93 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29577125 | 0.93 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29666169 | 0.93 | GHSR (0.63) | GHSRNPY1RNPY2RNPY4RERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | GHSR 484/4885NPY1R 1575/4885NPY2R 1800/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | GHSR 105/4885NPY1R 361/4885NPY2R 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.